Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05957887
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Sponsor
- Mohamed Nabil Elkholy
- Registry
-
NCT05957887
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt
- Registry status
- Unknown status
Technical summary
Registry record NCT05957887. Randomized; no masking; primary purpose treatment. Start 2022-04-15 (actual); primary completion 2025-03-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
- Condition
- STEMI
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Mohamed Nabil Elkholy
Record details
- Record id
cardio:ct-nct05957887- Content hash
c8563c58c07d51bdfae882b6fbdf4caeeee247ef9c823f3b1895b10e1b2be4a7